Clinical Scorecard: Identification of T-cell Neoplasms via Flow Cytometry Using Dual Staining for T-cell Constant β Chains TRBC1 and TRBC2

At a Glance

Key Highlights

• Dual staining for TRBC1 and TRBC2 enables confident identification of clonal T-cell populations analogous to B-cell light chain restriction.
• Anti-TRBC1 (JOVI.1) and engineered anti-TRBC2 antibodies provide specific, sensitive detection of respective TCR β chain isoforms.
• Dual assessment eliminates spurious TRBC-dim subsets seen in TRBC1-only staining, improving diagnostic accuracy and determination of targetable isoform.

Guideline-Based Recommendations

Diagnosis

• Use flow cytometry with dual anti-TRBC1 and anti-TRBC2 antibodies to detect T-cell clonality in suspected T-cell neoplasms.
• Correlate immunophenotypic findings with clinical and ancillary laboratory data for confident diagnosis.
• Avoid reliance on TCR gene rearrangement PCR alone due to interpretative challenges and false positives.

Management

• Identify the TRBC isoform expressed by malignant T-cells to inform potential targeted therapies, including CAR T-cell approaches.
• Consider TRBC1 or TRBC2 specificity when designing immunotherapies to preserve normal T-cell immunity.

Monitoring & Follow-up

• Employ flow cytometry with TRBC1/TRBC2 dual staining to monitor disease burden and clonal T-cell populations during treatment.

Risks

• Be aware that atypical T-cell populations can occur in reactive conditions, requiring careful interpretation.
• Recognize limitations of prior methods (e.g., TCR-Vβ repertoire analysis) including labor intensity, cost, and sensitivity.

Patient & Prescribing Data

Patients with suspected or confirmed T-cell lymphoproliferative disorders undergoing diagnostic evaluation

Determination of TRBC isoform expression guides development and application of isoform-specific CAR T-cell therapies targeting malignant T-cells while sparing normal T-cell subsets.

Clinical Best Practices

• Incorporate dual TRBC1 and TRBC2 antibody staining in routine flow cytometry panels for T-cell neoplasm diagnosis.
• Use engineered anti-TRBC2 antibody with validated specificity and affinity alongside JOVI.1 anti-TRBC1 antibody.
• Interpret flow cytometry results in conjunction with clinical context and other laboratory findings to avoid misdiagnosis.
• Utilize dual staining to accurately identify clonal T-cell populations and determine targetable TRBC isoform for personalized therapy.

References

• Flow cytometric detection of T-cell clonality using TRBC1 and TRBC2 antibodies
• JOVI.1 antibody specificity and CAR T-cell development targeting TRBC1
• Challenges in T-cell receptor gene rearrangement PCR for clonality assessment